Constitutively active MyD88/CD40 costimulation enhances expansion and efficacy of chimeric antigen receptor T cells targeting hematological malignancies-Reference-Cited by-同舟云学术

Constitutively active MyD88/CD40 costimulation enhances expansion and efficacy of chimeric antigen receptor T cells targeting hematological malignancies

Published:2019-02-28 Issue:9 Volume:33 Page:2195-2207
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Collinson-Pautz Matthew R.,Chang Wei-Chun,Lu An,Khalil Mariam,Crisostomo Jeannette W.,Lin Pei-Yi,Mahendravada Aruna,Shinners Nicholas P.,Brandt Mary E.,Zhang Ming,Duong MyLinh,Bayle J. Henri,Slawin Kevin M.,Spencer David M.,Foster Aaron E.

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/s41375-019-0417-9.pdf

Reference30 articles.

1. June CH, Sadelain M. Chimeric antigen receptor therapy. N Engl J Med. 2018;379:64–73.

2. Park JH, Rivière I, Gonen M, Wang X, Sénéchal B, Curran KJ, et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med. 2018;378:449–59.

3. Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378:439–48.

4. Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377:2531–44.

5. Foster AE, Mahendravada A, Shinners NP, Chang W-C, Crisostomo J, Lu A, et al. Regulated expansion and survival of chimeric antigen receptor-modified T cells using small molecule-dependent inducible MyD88/CD40. Mol Ther. 2017;25:2176–88.

Cited by 60 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Strategies for Improving CAR T Cell Persistence in Solid Tumors;Cancers;2024-08-16

2. Altered cancer metabolism and implications for next-generation CAR T-cell therapies;Pharmacology & Therapeutics;2024-07

3. Toll-like receptor 4 signaling activation domains promote CAR T cell function against solid tumors;Molecular Therapy: Oncology;2024-06

4. Deletion of MyD88 in T Cells Improves Antitumor Activity in Melanoma;The American Journal of Pathology;2024-06

5. CAR products from novel sources: a new avenue for the breakthrough in cancer immunotherapy;Frontiers in Immunology;2024-04-11